As per DelveInsight, the Sciatica Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Sciatica in the 7MM.
DelveInsight’s “Sciatica Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sciatica market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Sciatica market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key highlights from the Sciatica Market Report:
-
The sciatica market is expected to grow significantly during the forecast period (2023–2032), driven by the anticipated launch of new therapies from companies such as Scilex Pharmaceuticals, Sollis Therapeutics, Spine Thera, Sinfonia Biotherapeutics, and others with assets in advanced stages of development.
-
According to DelveInsight analysts, there has been a recent increase in sciatica cases, likely due to greater awareness and improved understanding of the condition.
-
Current treatment options for sciatica include corticosteroids, muscle relaxants, NSAIDs, opioid analgesics, and antidepressants, aimed at alleviating pain and managing inflammation. However, the sciatica treatment market experienced a setback during the COVID-19 pandemic, which led to reduced patient visits and diagnoses.
-
Sciatica companies working in the sciatica market are Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kolon Life Science, Teijin America, and others.
-
In Nov 2023, Scilex Holding Company announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). The Company has reached agreement with the FDA on the path forward to advance the clinical development of SP-102 and on the requirements to file a New Drug Application (“NDA”).
Read detailed insights on Sciatica market outlook 2032 @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-Sciatica-market
Sciatica Overview
Sciatica is characterized by pain that radiates along the sciatic nerve, which extends from the lower back through the hips and buttocks and down each leg. This pain is often described as shooting and typically affects only one side of the body. Sciatica is usually caused by compression of the lumbar nerves L4 or L5 or the sacral nerve S1. Less frequently, it may result from compression of sacral nerves S2 or S3 or the sciatic nerve itself. Contributing factors include age-related spinal changes, obesity, heavy lifting occupations, prolonged sitting, and diabetes. Most cases of sciatica stem from a spinal disc bulge or herniation, though other causes can include spondylolisthesis, musculoskeletal pain disorders, piriformis syndrome, pelvic tumors, and pregnancy. Sciatica is categorized into acute, chronic, alternating, bilateral, and wallet sciatica. Diagnosis typically involves a physical examination and a review of the patient’s symptom history.
To diagnose sciatica, physicians use physical examinations, medical history, and imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), and X-rays. These imaging techniques help visualize spinal structures and rule out conditions like herniated discs, spinal stenosis, or other abnormalities compressing the sciatic nerve. Nerve block injections can also be used for accurate diagnosis. However, diagnosing sciatica presents challenges, including distinguishing it from other conditions and managing risks such as bleeding, nerve damage, and spinal cord injury.
Treatment for sciatica often involves pharmacological therapies, including opioids, muscle relaxants, NSAIDs, steroids, antidepressants, and painkillers, to alleviate pain. Surgical options, such as discectomy, can provide pain relief for up to two years for patients with sciatica due to herniated discs or spinal stenosis. Despite available treatments, there remains a significant unmet need for approved therapies and more targeted treatment approaches.
Sciatica Epidemiology Insights:
-
Clarke et al. (2016) report that 54.5% of adults in the US experience musculoskeletal pain disorders, which include conditions such as lower back pain, sciatica, neck pain, and joint pain. These estimates are based on data from the National Health Interview Survey (2012), which surveyed the US adult population. Approximately 12 million individuals in the US are affected by sciatica.
-
Koes et al. (2007) note that in 90% of sciatica cases, the condition is caused by a herniated spinal disc compressing one of the lumbar or sacral nerve roots.
-
Davis et al. (2022) find that sciatica affects both genders equally, with a lifetime incidence rate ranging from 10% to 15%.
-
In Japan, Matsudaira et al. (2013) analyzed data from a prospective cohort study on occupation-related back pain and found that 18.4% of eligible participants reported a new episode of sciatica among Japanese workers.
Sciatica Emerging Drugs
Learn How the Sciatica Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/sciatica-market
Sciatica Market Outlook
Several factors drive the growth of the sciatica treatment market. Sedentary lifestyles, characterized by prolonged sitting, and an increase in herniated discs, along with other risk factors such as occupations involving heavy lifting and advancing age, contribute to the high prevalence of both acute and chronic sciatica.
Increased awareness and understanding of sciatica among patients and healthcare professionals have led to earlier diagnosis and treatment. Enhanced diagnostic techniques and greater healthcare access have also played a role in identifying more cases, thereby boosting demand for sciatica treatments.
The growing global geriatric population is a significant factor influencing the market, as older adults are more susceptible to conditions like herniated discs and degenerative disc diseases, common causes of sciatica. Commonly prescribed medications for managing sciatica include non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, opioid analgesics, benzodiazepines, systemic corticosteroids, antidepressants, and anticonvulsants.
Despite these growth drivers, challenges remain, including the lack of approved therapies for sciatica. Additionally, some patients opt for non-medical treatments such as physical therapy, injections, non-surgical and surgical options, and alternative therapies like chiropractic care or acupuncture, which can impact demand for conventional medical treatments. The absence of universally accepted treatment guidelines has led to varying approaches among healthcare professionals, resulting in inconsistent care and potentially suboptimal outcomes. The sciatica treatment market also faced setbacks during the COVID-19 pandemic due to reduced hospital visits.
According to DelveInsight, the sciatica market across the 7MM is expected to experience significant changes during the study period from 2032 to 2032.
Leading Players in the Sciatica Therapeutics Market Include:
Sciatica Companies working in the market are Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera, Kolon Life Science, Teijin America, and others.
Sciatica Report Covers the In-depth Assessment of the Emerging Sciatica Drugs & Key Companies. Download the Sciatica Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/sciatica-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Sciatica Competitive Intelligence Analysis
4. Sciatica Market Overview at a Glance
5. Sciatica Disease Background and Overview
6. Sciatica Patient Journey
7. Sciatica Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Sciatica Treatment Algorithm, Current Treatment, and Medical Practices
9. Sciatica Unmet Needs
10. Key Endpoints of Sciatica Treatment
11. Sciatica Marketed Products
12. Sciatica Emerging Drugs and Latest Therapeutic Advances
13. Sciatica Seven Major Market Analysis
14. Attribute Analysis
15. Sciatica Market Outlook (In US, EU5, and Japan)
16. Sciatica Access and Reimbursement Overview
17. KOL Views on the Sciatica Market
18. Sciatica Market Drivers
19. Sciatica Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Sciatica Market | Sciatica Therapies, Clinical trials, Sciatica prevalence, Sciatica Treatment, Sciatica Companies | Scilex Holding Company, Seikagaku Corporation, Sollis Therapeutics, SpineThera
